Literature DB >> 30456029

Natural History, Multimodal Management, and Quality of Life Outcomes of Trigeminal Schwannomas.

Serge Makarenko1, Vincent Ye1, Ryojo Akagami1.   

Abstract

Background  Trigeminal schwannomas are the second most common among intracranial schwannomas. These can arise from anywhere between the root and the distal extracranial branches of the trigeminal nerve. Clinical presentation depends on location and size, including but not limited to facial hypesthesia or pain, headaches, dizziness, ataxia, and diplopia. Literature is strikingly scant discussing the natural history of these lesions, while the treatment goals are heavily dependent on tumor presentation. Management decisions must be individualized to each tumor and each patient, while attempting to maximize the quality of life. We present the natural history of these lesions as well as their management by surgical resection or radiation therapy, and report long-term quality of life outcomes. Methods  Between 2001 and 2015, 24 patients (66.7% female) with trigeminal schwannomas were diagnosed and managed at Vancouver General Hospital. We analyzed the clinical presentation, surgical results, resection rates, patient quality of life, and complications. To complete the evaluation, we prospectively collected 36-Item Short Form Health Survey (SF-36) quality of life assessments for comparison. Results  We identified 12 patients treated with a craniotomy and surgical resection, 4 were treated with radiation therapy, while 8 patients were followed by observation. Mean age of study cohort was 49.2 years (range, 23-79 years), and most patients presented with facial hypesthesia (54.2%) and headaches (37.5%), while 37.5% were incidental findings. There were no major differences in patient demographics between the three groups. Patients offered surgery had larger lesions (mean diameter, 3.4 ± 1.1 cm) when compared with those that were irradiated or observed, and were more likely to have extracranial extension. Overall patient quality of life improved following treatment (ΔSF-36 + 12.9) at 3.9 years. Conclusions  The treatment goals of trigeminal schwannomas focus on improvement in neurologic symptoms, relief of mass effect, and preservation of cranial nerve function. We demonstrate that smaller lesions found incidentally with minimal symptoms can be followed safely with serial imaging, with 1 of 9 (11.1%) progressing to require treatment over the course of 7.1 years. Management of trigeminal schwannomas should be individualized with an involvement of a multidisciplinary skull base team.

Entities:  

Keywords:  observation; quality of life; radiation; schwannoma; surgery; trigeminal

Year:  2018        PMID: 30456029      PMCID: PMC6239870          DOI: 10.1055/s-0038-1651503

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  32 in total

1.  Stereotactic radiosurgery for trigeminal schwannomas.

Authors:  John Yianni; Eduard Bogdan Dinca; Jeremy Rowe; Matthias Radatz; Andras A Kemeny
Journal:  Acta Neurochir (Wien)       Date:  2011-09-15       Impact factor: 2.216

Review 2.  Endoscopic Endonasal Resection of Trigeminal Schwannomas.

Authors:  Shaan M Raza; Muhamad A Amine; Vijay Anand; Theodore H Schwartz
Journal:  Neurosurg Clin N Am       Date:  2015-05-14       Impact factor: 2.509

3.  Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Authors:  W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

Review 4.  Trigeminal schwannomas: skull base approaches and operative results in 105 patients.

Authors:  Masahiko Wanibuchi; Takanori Fukushima; Ali R Zomordi; Yoichi Nonaka; Allan H Friedman
Journal:  Neurosurgery       Date:  2012-03       Impact factor: 4.654

Review 5.  Trigeminal schwannoma. Surgical series of 14 cases with review of the literature.

Authors:  P C McCormick; J A Bello; K D Post
Journal:  J Neurosurg       Date:  1988-12       Impact factor: 5.115

6.  Trigeminal schwannomas: experience with 57 cases and a review of the literature.

Authors:  Raita Fukaya; Kazunari Yoshida; Takayuki Ohira; Takeshi Kawase
Journal:  Neurosurg Rev       Date:  2010-10-21       Impact factor: 3.042

7.  Radiation tolerance limits of the brainstem.

Authors:  Manish S Sharma; Douglas Kondziolka; Aftaab Khan; Hideyuki Kano; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  Neurosurgery       Date:  2008-10       Impact factor: 4.654

8.  Stereotactic radiotherapy for intracranial nonacoustic schwannomas including facial nerve schwannoma.

Authors:  Kentaro Nishioka; Daisuke Abo; Hidefumi Aoyama; Yasushi Furuta; Rikiya Onimaru; Shunsuke Onodera; Yutaka Sawamura; Masayori Ishikawa; Satoshi Fukuda; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-20       Impact factor: 7.038

9.  The patient's perspective after vestibular schwannoma removal: quality of life and implications for management.

Authors:  R M Irving; G J Beynon; L Viani; D G Hardy; D M Baguley; D A Moffat
Journal:  Am J Otol       Date:  1995-05

10.  Conservative treatment of vestibular schwannoma: a follow-up study on clinical and quality-of-life outcome.

Authors:  Willem P Godefroy; Adrian A Kaptein; Justine J Vogel; Andel G L van der Mey
Journal:  Otol Neurotol       Date:  2009-10       Impact factor: 2.311

View more
  2 in total

1.  Pediatric multicompartmental trigeminal schwannoma: illustrative case.

Authors:  Alexander P Landry; Vincent C Ye; Kerry A Vaughan; James M Drake; Peter B Dirks; Michael D Cusimano
Journal:  J Neurosurg Case Lessons       Date:  2021-05-17

Review 2.  Trends in the Management of Non-Vestibular Skull Base and Intracranial Schwannomas.

Authors:  Carlos Suárez; Fernando López; William M Mendenhall; Simon Andreasen; Lauge Hjorth Mikkelsen; Johannes A Langendijk; Stefano Bondi; Juan P Rodrigo; Leif Bäck; Antti A Mäkitie; Verónica Fernández-Alvarez; Andrés Coca-Pelaz; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.